BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35874638)

  • 1. Identification of APC Mutation as a Potential Predictor for Immunotherapy in Colorectal Cancer.
    Feng F; Sun H; Zhao Z; Sun C; Zhao Y; Lin H; Yang J; Xiao Y; Wang W; Wu D
    J Oncol; 2022; 2022():6567998. PubMed ID: 35874638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type APC Is Associated with Poor Survival in Metastatic Microsatellite Stable Colorectal Cancer.
    Wang C; Ouyang C; Cho M; Ji J; Sandhu J; Goel A; Kahn M; Fakih M
    Oncologist; 2021 Mar; 26(3):208-214. PubMed ID: 33230914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration in the Immune Microenvironment Based on APC Status in MSS/pMMR Colon Cancer.
    Lin H; Cao B
    Dis Markers; 2022; 2022():3592990. PubMed ID: 35937946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.
    Lin A; Zhang H; Hu X; Chen X; Wu G; Luo P; Zhang J
    Pharmacol Res; 2020 Sep; 159():105028. PubMed ID: 32569820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. To Identify Adenomatous Polyposis Coli Gene Mutation as a Predictive Marker of Endometrial Cancer Immunotherapy.
    Song Y; Huang J; Wang K; Li Y
    Front Cell Dev Biol; 2022; 10():935650. PubMed ID: 35938175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APC mutation correlated with poor response of immunotherapy in colon cancer.
    Li B; Zhang G; Xu X
    BMC Gastroenterol; 2023 Mar; 23(1):95. PubMed ID: 36977982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy.
    Hua H; He W; Chen N; He Y; Wu G; Ye F; Zhou X; Li Y; Ding Y; Zhong W; Teng L; Jiang W; Sheng Q
    Front Immunol; 2022; 13():974793. PubMed ID: 36700211
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Zimmer K; Puccini A; Xiu J; Baca Y; Spizzo G; Lenz HJ; Battaglin F; Goldberg RM; Grothey A; Shields AF; Salem ME; Marshall JL; Korn WM; Wolf D; Kocher F; Seeber A
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer.
    Jorissen RN; Christie M; Mouradov D; Sakthianandeswaren A; Li S; Love C; Xu ZZ; Molloy PL; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Burgess AW; Busam D; Zhao Q; Strausberg RL; Lipton L; Desai J; Gibbs P; Sieber OM
    Br J Cancer; 2015 Sep; 113(6):979-88. PubMed ID: 26305864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Huang K; Ding S; Chen K; Guo C; Wu M; Zhang R; Wang L; Fu Y; Xiao J; Liu X
    Am J Cancer Res; 2023; 13(11):5549-5558. PubMed ID: 38058823
    [No Abstract]   [Full Text] [Related]  

  • 15. Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
    Heeke AL; Xiu J; Elliott A; Korn WM; Lynce F; Pohlmann PR; Isaacs C; Swain SM; Vidal G; Schwartzberg LS; Tan AR
    Breast Cancer Res Treat; 2020 Nov; 184(2):265-275. PubMed ID: 32776290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APC and CTNNB1 mutations in a large series of sporadic colorectal carcinomas stratified by the microsatellite instability status.
    Løvig T; Meling GI; Diep CB; Thorstensen L; Norheim Andersen S; Lothe RA; Rognum TO
    Scand J Gastroenterol; 2002 Oct; 37(10):1184-93. PubMed ID: 12408524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients.
    Li K; Liu J; Wu L; Xiao Y; Li J; Du H; Zhao Z; Sun C; Zhao Y; Yang J; Wu D; Zhao Z; Chen B
    Cancer Cell Int; 2022 Mar; 22(1):138. PubMed ID: 35346207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
    Nava Rodrigues D; Rescigno P; Liu D; Yuan W; Carreira S; Lambros MB; Seed G; Mateo J; Riisnaes R; Mullane S; Margolis C; Miao D; Miranda S; Dolling D; Clarke M; Bertan C; Crespo M; Boysen G; Ferreira A; Sharp A; Figueiredo I; Keliher D; Aldubayan S; Burke KP; Sumanasuriya S; Fontes MS; Bianchini D; Zafeiriou Z; Teixeira Mendes LS; Mouw K; Schweizer MT; Pritchard CC; Salipante S; Taplin ME; Beltran H; Rubin MA; Cieslik M; Robinson D; Heath E; Schultz N; Armenia J; Abida W; Scher H; Lord C; D'Andrea A; Sawyers CL; Chinnaiyan AM; Alimonti A; Nelson PS; Drake CG; Van Allen EM; de Bono JS
    J Clin Invest; 2018 Oct; 128(10):4441-4453. PubMed ID: 30179225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.